LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...
Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback